1. Introduction {#sec1}
===============

*Vernonia anthelmintica* Willd., a member of the family Asteraceae, is an erect forb or shrub where more than 1000 species of the genus*Vernonia* were widely distributed in subtropical and tropical areas throughout Asia and Africa \[[@B1]--[@B3]\]. In traditional Uyghur medicine (TUM), seeds of the*Vernonia anthelmintica* Willd. (*V. anthelmintica*) were used as a herbal medicine with the common name of "Kaliziri" for the treatment of diabetes mellitus, leukoderma, skin disease, fever, worm infection, and kidney trouble \[[@B4]\].

In recent years with the development of traditional medicine in China,*V. anthelmintica*has been widely used in the medicinal formula for the treatment of vitiligo, such as "Kursi babuqi" and "Injection of Kaliziri." Wang et al. \[[@B5]\] treated 157 patients with "Kursi babuqi" for three months and that showed that effective rate of treatment group was 56%. Liu et al. \[[@B6]\] reported that 445 patients of vitiligo vulgaris were treated with "Kursi babuqi" for one year, and effectiveness of treatment reached 93.5%. For the other formulation of*V. anthelmintica*, "injection of Kaliziri" was applied to the patient combined with UV treatment, and effective rate of treatment group was 70.4% \[[@B7]\]. The herb also was recorded in the book of "Ministry of PRC Health and Drug standards" \[[@B8], [@B9]\] and also was recorded with various biological effects, including antiarthritic \[[@B1]\], antibacterial, anthelmintic, analgesic, anti-inflammatory, antioxidant, antidiabetic, antihyperlipidemic, and cytotoxic activities \[[@B10]--[@B15]\].

Previous phytochemical investigations of the herb have shown that it contains flavones \[[@B16]\], caffeoylquinic acid derivatives \[[@B17]\], sesquiterpene, triterpenoids, elemanolide sesquiterpenoids, and guaianolide sesquiterpenoids \[[@B1]\]. It was reported that few compounds were isolated from the herb which able to promote melanin synthesis activity \[[@B18], [@B19]\].

Although many researches about*V. anthelmintica*seeds were found, no more scientific results were reported about the chemical composition and bioactivity of volatile oil from*V. anthelmintica* seeds (AVO). To search active components for the treatment of vitiligo we studied volatile components of*V. anthelmintica* and its bioactivities. In this research, we studied the AVO effects on melanogenesis in B16 cells and investigated its chemical composition by GC-QTOF-MS method.

2. Materials and Methods {#sec2}
========================

2.1. Plant Material {#sec2.1}
-------------------

The seeds of*V. anthelmintica* (batch number: Z30031501) were purchased in March 2016, from Xinjiang Meditsina Uyghur pharmaceutical Co., Ltd, Xinjiang, China. Voucher specimen has been deposited at the herbarium (Voucher no. WY02316), Xinjiang Institute of Ecology and Geography. Plant materials were identified by Professor Feng Ying from Xinjiang Institute of Ecology and Geography, Chinese Academy of Science.

2.2. Reagents {#sec2.2}
-------------

DMSO (D8418) was purchased from Sigma-Aldrich (St. Louis, MO, USA). A cell counting kit (FC101) was purchased from TransGen Biotechnology (Beijing, China). C7-C30 saturated alkanes standard 1ml (SUPELCO, USA),*n*-hexane (analytical grade).

2.3. Extraction and Sample Preparation {#sec2.3}
--------------------------------------

The powdered*V. anthelmintica* seeds (100g) were extracted by volatile oil extractor with 1400 mL water for 6h. The oil was collected and dried over anhydrous sodium sulfate and dissolved in dimethyl sulfoxide (DMSO) to make a stock solution and then stored at -20°C until use. 50mg·mL^−1^ stock solution of AVO in DMSO was used for cell experiment. Fourfold dilution of AVO with*n*-hexane was used for chemical analysis.

2.4. Cell Culture {#sec2.4}
-----------------

The murine B16 melanoma cells were purchased from the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China, No. TCM2) and were cultured in high glucose Dulbecco\'s modified eagle medium (HG-DMEM, Gibco) supplemented with 10% FBS (BI, Biological Industries), 100 *μ*g•mL^−1^ streptomycin, and 100 U•mL^−1^ penicillin (Gibco, Cat. No. 15140-122). The cells were maintained in a humidified incubator with 5% CO2 at 37°C, and they were subcultured every 2 days to maintain logarithmic growth.

2.5. Cell Viability Assay {#sec2.5}
-------------------------

The viability of cultured B16 cells was assayed by adding CCK-8 solution. Generally, B16 cells were plated in 96-well plate at a density of 5×10^3^ cells per well and incubated for 24 h. Test samples were added with different concentration, and the cells were incubated for 24h. After discarding the culture medium of the cells, 10*μ*L of CCK-8 solution was added into each well and the cells were incubated at 37°C for 2h. The absorbance was determined at 450 nm using microplate spectrophotometer (Spectra Max M5, Molecular Devices Company, Sunnyvale, CA, USA). The absorbance of cells without treatment was regarded as 100% of cell survival. Each treatment was performed in triplicate, and each experiment was repeated for three times.

2.6. Melanin Content Assay {#sec2.6}
--------------------------

The B16 cells were seeded in a six-well plate (2×10^5^ cells/ well) for 12h, after renewing the culture medium of the cells treated with different concentrations of AVO for 48h and washed with ice-cold PBS twice. Cells were lysed \[[@B16]\], and each lysate was taken 150*μ*l into a 96-well plate and measured; optical density of the solubilized melanin was measured at 405 nm by a multiplate reader. BCA Protein Assay Kit (Biomed, Beijing, China) was used to determine the protein concentration of each sample. The melanin content was normalized to the cellular protein concentration (abs melanin/*μ*g protein). The percentage value of the AVO treated cells was calculated with respect to the negative control \[[@B20]\].

2.7. Tyrosinase Activity Assay {#sec2.7}
------------------------------

The tyrosinase activity was estimated by measuring the rate of L-DOPA oxidation \[[@B21], [@B22]\]. B16 cells were seeded in a six-well plate at a density of 3×10^5^ cells per well and allowed to attach for 12h. Cultured B16 cells were incubated in the absence or presence of AVO for 24h, and the adherent cells were washed with ice-cold PBS twice and lysed with 100*μ*L lysis buffer (1% sodium deoxycholate and 1% TritonX-100 in PBS) for 30 min at 80°C, and each lysate was centrifuged at 12,000×g for 15 min to obtain the supernatant. Ninety microliters (90 *μ*L) of the supernatant was added to 10 *μ*L of freshly prepared 10 mmol·mL^−1^ L-DOPA solution in each well of a 96-well plate. Then, the cells were incubated at 37°C in dark for 30 min and the absorbance of dopachrome was measured at 490 nm using a microplate reader. Data was calculated using the following formula: tyrosinase activity (%) = (OD 490 of sample/OD 490 of control) × 100.

2.8. GC-QTOF-MS Analysis {#sec2.8}
------------------------

For the chemical analysis of AVO, an Agilent 7200 GC-QTOF-MS (Agilent, SantaClara, USA) was used, equipped with a HP-INNOWax capillary column (Agilent, 60 m×0.25 mm i.d., 0.25 *μ*m film thickness, polyethylene glycol stationary phase). The carrier gas was 99.99% high purity Helium with a flow rate of 0.8 mL·min^−1^. GC injection was performed in pulsed split mode (split rate 10:1, purge flow to split vent 5ML·min^−1^). The following GC temperature gradient was used: 60°C for 2 min, 2°C/min to 80°C, 8°C/min to 180°C, 4°C/min to 240°C, and holding at 240°C for 30min. The temperatures of the injector, the transfer line, and the ion source were set to 250, 280, and 230°C, respectively. The total run time was 65 min with a solvent delay of 5 min. The QTOF mass spectrum was recorded at five scans per second with a mass-to-charge ratio 50-500 m/z mass acquisition range. Ionization was operated in electron impact ionization (EI) mode at 70 eV. 1.2*μ*L AVO sample solution was injected in to GC-QTOF-MS system for analysis, in the same chromatographic conditions that C7-C30*n*-alkanes standard used for calculating the retention times indices of GC peak from sample (Supplementary [Figure 2](#supplementary-material-1){ref-type="supplementary-material"}) \[[@B23], [@B24]\].

2.9. Data Analysis {#sec2.9}
------------------

The results of cell experiment were expressed as the mean ± SD, and the statistical analysis was performed by one-way ANOVA followed by a Tukey post hoc test for multiple comparison tests. Significant differences were accepted when P \< 0.05. The retention indices (I) of every GC peaks were calculated with retention times of C7-C30*n*-alkanes standard that were injected at the same chromatographic conditions. Then, the mass spectral data were processed using Mass Hunter Qualitative Analysis B.070. The compounds were identified by comparing with mass spectra NIST14. L library data \[[@B23]\] and validated with the published compounds index data. The relative percentage of compounds was normalized by peak area.$$\begin{matrix}
{I = 100 \times \frac{lg\, t^{/}\left( i \right) - lg\, t^{/}\left( n \right)}{lg\, t^{/}\left( {n + 1} \right) - lg\, t^{/}\left( n \right)}} \\
\end{matrix}$$where *I* is the retention index of the components to be tested and*(i)* is the adjusted retention time (min) of the components to be tested;*n* and*n+*1 are the carbon amounts of*n*-alkanes before and after the unknowns effused, respectively; *t*′*(n)* and *t*′*(n+*1) are the No.*n* and No.*n+*1 carbon retention times of*n*-alkanes, respectively \[[@B25], [@B26]\].

3. Results {#sec3}
==========

3.1. Cell Viability of Melanoma Cells Induced by AVO {#sec3.1}
----------------------------------------------------

Our results showed that murine melanoma B16 cells treated with concentration of 1-10*μ*g·mL^−1^ AVO for 24h did not induce any changes in cell viability. At the concentration of 10-30*μ*g·mL^−1^, the cell viability was around 80 to 90 percent which display slight cytotoxicity. Compared with untreated cells, with the treatment of 50*μ*g·mL^−1^ of AVO cell viability was only 56 percent and indicated relative higher cytotoxicity ([Figure 1](#fig1){ref-type="fig"}). Therefore, the concentrations at 10-30*μ*g·mL^−1^ are suitable for further evaluating the effects of AVO on tyrosinase activity and melanin synthesis in B16 cells.

3.2. AVO Enhances Intracellular Melanin Content and Tyrosinase Activity {#sec3.2}
-----------------------------------------------------------------------

In the melanin content assay, the absorbance of the same number of cells across AVO concentrations (10-30*μ*g·mL^−1^) was measured in order to exclude the possibility that a rise in melanin content may be induced by the cell proliferating effect of AVO. We found that melanin levels were increased in B16 cells in a dose-dependent manner after the treatment of AVO ([Figure 2(a)](#fig2){ref-type="fig"}). At the concentration of 10-30*μ*g·mL^−1^, the melanin content showed concentration-dependent increase, while the concentration of 20-30*μ*g·mL^−1^ showed significant increase in melanin content. The effect of AVO on tyrosinase activity did not show significant difference compared with untreated group ([Figure 2(b)](#fig2){ref-type="fig"}); however it showed a rise trend.

3.3. GC-QTOF-MS Analysis {#sec3.3}
------------------------

The result of AVO was obtained at a yield of 0.15% w/w. The 86 peaks were separated in GC as shown [Figure 3](#fig3){ref-type="fig"} and preliminarily identified 64 compounds by QTOF-MS which account for 95.15% of total peak area ([Table 1](#tab1){ref-type="table"}). According to the chemical composition analysis of AVO, the terpenoids accounted for 73.53%, phenolics 8.07%, ethers 5.31%, esters 3.76%, hydrocarbons 3.54%, aromatics 0.42%, ketones 0.39%, and acids 0.15%.The main chemical components of AVO were caryophyllene 23.73%, sabinen18.15%, *α*-thujene 6.57%, thymol 5.29%, limonene4.92%, and 4-epi-*α*-acoradiene 4.98%.

4. Discussion {#sec4}
=============

Vitiligo is an acquired, progressive, multifactorial, and depigmentation disorder characterized by the appearance of circumscribed white macules in the skin caused by chronic, progressive loss of functional melanocytes in the epidermis \[[@B27], [@B28]\]. The etiology of vitiligo is poorly understood. Also, the numerous factors have been implicated in the development of vitiligo, including trauma, stress, exposure to sunlight for long time, skin infections, neural stress, cancer, melatonin receptors dysfunction, some drugs, and endocrine diseases and toxic compounds. These causal factors may act independently or in concert \[[@B29]\]. The pigmentation of the skin provides many valuable function; perhaps foremost among these is the photo protection of underlying tissues from ultraviolet (UV) radiation. Melanocytes respond to a wide variety of intrinsic and extrinsic factors produced by the environment or by neighboring cells in the skin, including UV, stimulating hormone (MSH), agouti signal protein (ASP), endothelin 1 (ET1), dickkopf 1 (DKK1), a wide variety of growth factors, and cytokines \[[@B4]\]. Melanin biosynthesis is catalyzed by three melanocyte-specific enzymes: TYR, tyrosinase-related protein 1 (TRP-1), and TRP-2 \[[@B4]\]. The tyrosinase playing an essential role in melanocyte melanin biosynthesis has been known for many decades. Therefore, tyrosinase is an important index for the treatment and diagnosis of vitiligo. In our result the AVO increased the melanin synthesis and slightly impacted tyrosinase activity but did not make a significant difference with untreated group, so, we considered that AVO can promote melanin biosynthesis may relate with other enzyme (TRP-1, TRP-2). It provided potential research value.

Melanocyte loss and its underlying pathogenic mechanisms are not fully understood \[[@B36]\]. Both intrinsic (gene polymorphisms/mutations, autoimmunity, autotoxicity of melanocytes, and oxidative stress) and extrinsic factors are known to contribute to vitiligo, and it is recognized that hypersensitivity to oxidative stress has an important role in ultimate destruction of epidermal melanocytes. Oxidative stress has been demonstrated to be enhanced in pathological melanocytes and closely related to melanocyte apoptosis and autoimmune destruction \[[@B30]--[@B35]\]. Our preliminary result also suggests that AVO could protect B16 cells from H~2~O~2~-induced oxidative damage (Supplementary [Figure 1](#supplementary-material-1){ref-type="supplementary-material"}).

As volatiles, AVO was characterized by a strong odor. It is synthesized by plants as secondary metabolites and has been widely used owing to its bactericidal, virucidal, fungicidal, antiparasitic, insecticidal, anticancer, antioxidant, antidiabetic and cardiovascular effects \[[@B39]\]. The AVO was mainly composed of terpenoids occupying 73.53% of total chemical content, such as caryophyllene, sabinene, and limonene. Being natural compounds, the terpenoids were shown to have wide range of biological and pharmacological activities, including central effects, antimicrobial, and antitumor actions \[[@B37], [@B38]\]. In our results, high concentrations of AVO showed little cytotoxic properties in melanocytes. Therefore, we observed the protective effect of AVO on H~2~O~2~-induced B16 cells injury. Result showed that pretreatment of AVO reduced H~2~O~2~-induced cell injury in a dose-dependent manner (supplementary [Figure 1](#supplementary-material-1){ref-type="supplementary-material"}). From our result, we tentatively conclude that AVO could protect melanocytes from harmful factors in vitiligo like oxidative stress. This result is similar to the antitumor and antioxidant effect of terpenoids. So, we considered that the terpenoids were major biologically active compounds in AVO. Since AVO had possessed terpenoids such as caryophyllene, sabinen, 4-epi-*α*-acoradiene, *α*-thujene, and limonene, it is hypothesized that the unsaturated double bond in active ingredients of AVO may be responsible for its antioxidant properties ([Figure 4](#fig4){ref-type="fig"}). Caryophyllene as a main content in AVO provided extensive pharmacological effects. Dahham et al. \[[@B39]\] reported that compounds have anticancer, antioxidant, and antimicrobial activities. They observed the antiproliferative effect of caryophyllene on the cancer cell lines. Among the tested cancer cells, the compound demonstrated selective antiproliferative effect against three cancer cell lines, namely, HCT 116, PANC-1, and HT29 cells, whereas it exhibited either moderate or poor cytotoxic effects against ME-180, PC3, K562, and MCF-7. Noteworthily, the compound displayed low toxicity against the normal cell lines such as 3T3-L1 and RGC-5. The study concluded that caryophyllene has strong selective cytotoxic properties against human colorectal cancer cells. Based on this report and our result of AVO cell viability assay, we considered that caryophyllene may be responsible for AVO\'s biological effect. In addition, we employed the TCMSP database to check the ADME properties and targets for the main compounds of AVO (http://lsp.nwu.edu.cn/molecule.php?qn=193). Data showed that caryophyllene and limonene related some autoimmune diseases, genetic diseases, and corresponding targets (supplementary [Table 1](#supplementary-material-1){ref-type="supplementary-material"}), such as cardiovascular disease, arthritis, cancer, autoimmune cardiomyopathy, and Parkinson\'s disease. From the database, we could not correlate the exact relation between AVO active components and vitiligo or melanin loss disease. But according to the database information, we inferred that caryophyllene and limonene has immunomodulatory, antioxidant, and anticancer effects. Hence, we hypothesized that AVO increased melanin biosynthesis may be related to immunomodulatory and antioxidant effect from caryophyllene and limonene.

5. Conclusions {#sec5}
==============

According to the biological and chemical analysis of AVO, the AVO can increase melanin synthesis. It be may concluded that terpenoids rich chemical properties of AVO may be responsible for its biological effects.
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###### 

Supplementary Figure 1: AVO prevents cell death in H~2~O~2~-treted B16 cells. Cell viability was measured by a CCK-8 assay. The data are shown as the means + SD; n=3 and *∗∗∗* p \<0.001 compared with control group. Supplementary Figure 2: the GC peak of*n*-alkanes standard. Supplementary Table 1: related diseases and targets of caryophyllene and limonene.

###### 

Click here for additional data file.

![B16 melanoma cells were exposed to various concentrations of AVO (1, 5, 10, 20, 30, and 50*μ*g·mL^−1^) for 24h. Cell viability was measured by a CCK-8 assay. The data are shown as the means ± SD;*n*=3.](ECAM2018-6291281.001){#fig1}

![Cellular melanin synthesis (a) in B16 melanoma cells and concentration-dependent effect of AVO on tyrosinase activity (b). Cells were treated with 0.1% DMSO as a vehicle or with AVO at 10, 20, and 30*μ*g·mL^−1^ and 50*μ*M 8-MOP as a positive control. The data of melanin content is shown (a). The cells were then analyzed by tyrosinase activity assay (b). Each percentage value for treated cells is reported relative to that of 0.1% DMSO cells. The results have been shown as the means ± SD; n = 3, *∗∗* p \<0.01, and *∗∗∗* p \<0.001 compared with 0.1% DMSO cells.](ECAM2018-6291281.002){#fig2}

![The GC peak spectra of AVO.](ECAM2018-6291281.003){#fig3}

![The structure of mainly terpenoids in AVO.](ECAM2018-6291281.004){#fig4}

###### 

Volatile compositions in AVO.

       Compound                                                        RT(min)   Possible formula   RI     Content (%)
  ---- --------------------------------------------------------------- --------- ------------------ ------ -------------
  1    *α*-Thujene                                                     8.68      C~10~H~16~         1029   6.57
  2    Toluene                                                         9.22      C~7~H~8~           1049   0.08
  3    Camphene                                                        9.92      C~10~H~16~         1075   0.17
  4    Sabinene                                                        11.34     C~10~H~16~         1124   18.15
  5    *β*-Thujene                                                     11.56     C~10~H~16~         1131   1.08
  6    *α*-Phellandrene                                                12.71     C~10~H~16~         1169   0.53
  7    *α*-Terpine                                                     13.33     C~10~H~16~         1189   0.22
  8    Limonene                                                        13.92     C~10~H~16~         1209   4.92
  9    Eucalyptol                                                      14.21     C~10~H~18~O        1219   1.23
  10   Methoxyacetic acid,4-tetradecyl ester                           14.76     C~17~H~34~O~3~     1239   0.11
  11   *γ*-Terpinene                                                   15.22     C~10~H~16~         1255   0.48
  12   o-Cymene                                                        15.94     C~10~H~14~         1281   0.47
  13   Terpinolene                                                     16.24     C~10~H~16~         1292   0.47
  14   Isomenthone                                                     20.5      C~10~H~18~O        1481   0.28
  15   Copaene                                                         21.00     C~15~H~24~         1507   0.22
  16   Linalyl acetate                                                 21.64     C~12~H~20~O~2~     1543   0.94
  17   *α*-Gurjunene                                                   21.80     C~15~H~24~         1552   0.47
  18   Fenchol                                                         22.53     C~10~H~18~O        1593   0.17
  19   *β*-Elemene                                                     22.6      C~15~H~24~         1596   0.43
  20   cis-Caryophyllene                                               22.83     C~15~H~24~         1610   0.45
  21   L-terpinen-4-ol                                                 22.92     C~10~H~18~O        1615   0.99
  22   Caryophyllene                                                   23.14     C~15~H~24~         1628   23.73
  23   dl-Menthol                                                      23.42     C~10~H~20~O        1645   0.83
  24   Ginsinsene                                                      24.16     C~15~H~24~         1689   0.86
  25   4-epi-*α*-Acoradiene                                            24.32     C~15~H~24~         1699   4.98
  26   *α*-Terpinyl acetate                                            24.42     C~12~H~20~O~2~     1705   1.38
  27   Chamigren                                                       24.52     C~15~H~24~         1711   0.51
  28   *β*-Selinene                                                    24.6      C~15~H~24~         1716   0.22
  29   Valencene                                                       24.96     C~15~H~24~         1738   0.20
  30   Eremophilene                                                    25.06     C~15~H~24~         1743   0.09
  31   Bicyclogermacrene                                               25.18     C~15~H~24~         1750   0.18
  32   *δ*-Selinene                                                    25.22     C~15~H~24~         1753   0.11
  33   Piperitone                                                      25.3      C~10~H~16~O        1758   0.26
  34   (-)-Carvone                                                     25.37     C~10~H~14~O        1762   0.46
  35   *δ*-Cadinene                                                    25.62     C~15~H~24~         1777   0.33
  36   Octadecane                                                      25.81     C~18~H~38~         1788   0.20
  37   Cuminal                                                         26.22     C~10~H~12~O        1813   0.70
  38   *α*-Terpinen-7-al                                               26.46     C~10~H~14~O        1827   0.14
  39   Anethole                                                        26.85     C~10~H~12~O        1849   3.44
  40   2-Methyloctadecane                                              27.51     C~19~H~40~         1888   0.21
  41   Isosafrole                                                      27.77     C~10~H~10~O~2~     1903   0.21
  42   Alloaromadendrene oxide-(2)                                     29.74     C~15~H~24~O        2015   0.27
  43   Caryophyllene oxide                                             29.96     C~15~H~24~O        2026   1.39
  44   Globulol                                                        30.96     C~15~H~26~O        2081   0.35
  45   Phenol, 2-methoxy-4-propyl-                                     31.83     C~10~H~14~O~2~     2128   0.16
  46   Thunbergene                                                     32.56     C~20~H~32~         2167   0.11
  47   Thymol                                                          32.95     C~10~H~14~O        2187   5.29
  48   Verticiol                                                       33.27     C20H34O            2205   0.30
  49   Hexadecanoic acid, methyl ester                                 33.45     C~17~H~34~O~2~     2214   0.11
  50   Carvacrol                                                       33.58     C~10~H~14~O        2221   1.62
  51   Isophyllocladen                                                 33.88     C~20~H~32~         2236   1.25
  52   Cembrene A                                                      34.69     C~20~H~32~         2279   1.09
  53   2,4-Di-tert-butylphenol                                         35.2      C~14~H~22~O        2305   0.17
  54   *α*-Pinacene                                                    36.46     C~20~H~32~         2371   1.57
  55   Dill apiol                                                      36.66     C~12~H~14~O~4~     2382   0.33
  56   8,11,13-triene-18-Norabieta                                     37.94     C~19~H~28~         2446   0.16
  57   3,3,4,5,5,8-Hexamethyl-3,5,6,7-tetrahydro-S-indacen-1(2H)-one   39.17     C~18~H~24~O        2507   0.20
  58   *γ*-Thujaplicine                                                40.29     C~10~H~12~O~2~     2556   0.19
  59   Methyl dehydroabietate                                          43.25     C~21~H~30~O~2~     2673   1.22
  60   Kolavenol                                                       46.26     C~20~H~34~O        2771   0.34
  61   9-Ethyl-10-methylanthracene                                     46.50     C~17~H~16~         2778   0.10
  62   10,18-Bisnorabieta-5,7,9(10),11,13-pentaene                     47.56     C~17~H~16~         2809   0.19
  63   Retene                                                          48.65     C~18~H~18~         2836   1.12
  64   n-Hexadecanoic acid                                             51.02     C~16~H~32~O~2~     2895   0.15
                                                                                                           
       **Total**                                                                                           **95.15**

[^1]: Academic Editor: Francisco Solano
